Description of the medicine: Cavinton
Ethyl ester of apovinamic acid.
Synonyms: Vinpocetine, Vinpocetine, Vinpocetinum, Inex.
White crystalline powder, practically nerastorim in water, soluble in alcohol.
Cavinton (vinpocetine) is a semi-synthetic derivative of the deviccan alkaloid contained in the periwinkle plant (Vinica minor L. and Vinca erecta Rgl. Et Schmalth); Sem. Kutrovyh (Aposanaceae).
Previously, it was found that vinca extracts have vasodilator and hypotensive effect, have some sedative effect. The alkaloid vincamine (vinamino acid methyl ester) isolated from vinca was proposed for use (under the names "Devincan", "Minorin" - Devincan, Minorin) as a vasodilator. As a result of clinical studies, it was found that devinkan is particularly effective in disorders of cerebral circulation, and later the preparation Cavinton, which received the international name "Vinpocetine", was created.
Cavinton dilates the vessels of the brain, increases blood flow, improves the supply of oxygen to the brain, and also facilitates the utilization of glucose. Inhibiting phosphodiesterase, the drug leads to accumulation in the tissues of cAMP; Reduces aggregation of platelets. There is only a slight decrease in systemic blood pressure.
The vasodilating effect of Cavinton is associated with a direct relaxing effect on smooth muscles. The drug contributes to the enhancement of the metabolism of norepinephrine and serotonin in the brain tissues, reduces the pathologically increased blood viscosity, promotes deformability of erythrocytes.
Applied with neurological and mental disorders associated with disorders of cerebral circulation (after a stroke, posttraumatic, atherosclerotic origin); In memory disorders, dizziness, aphasia, etc .; With hypertensive encephalopathy, vasovegative symptoms in the climacteric period, etc.
In ophthalmologic practice, Cavinton is prescribed for atherosclerotic and angiospastic changes in the reticular and vascular membranes, degenerative changes in the yellow spot, secondary glaucoma associated with partial vascular thrombosis, and others.
It is also effective in reducing hearing of vascular or toxic (medicamentous) origin and dizziness of labyrinth origin.
Take inside in the form of tablets (5 mg) for 1 - 2 tablets 3 times a day. Maintenance dose - 1 tablet 3 times a day. Applied for a long time. Improvement is usually observed after 1 to 2 weeks; Course of treatment about 2 months or more.
Intravenous (drip only) is used in neurological practice with acute focal ischemic impairment of cerebral circulation, in the absence of hemorrhage. Initially, 10-20 mg (1 - 2 ampoules) in 500-1000 ml isotonic sodium chloride solution (drop infusion) is administered first. If necessary, appoint repeated (3 times a day) slow drip infusions, then switch to taking the drug inside.